Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International Ltd. ( (AU:NTI) ) has issued an announcement.
Neurotech International Ltd has made significant progress in developing NTI164, a potential treatment for Rett Syndrome, having received orphan drug designation from the FDA, which includes benefits like tax credits and market exclusivity. Despite a setback in obtaining similar designation for PANDAS/PANS, their trials show promising results in reversing immune dysregulation, highlighting NTI164’s potential in treating neurological disorders, which could enhance their market positioning and offer new opportunities if regulatory approvals are achieved.
More about Neurotech International Ltd.
Neurotech International Ltd is a clinical-stage biopharmaceutical company primarily focused on developing treatments for pediatric neurological disorders. The company is notably engaged in addressing conditions such as Rett Syndrome, PANDAS/PANS, and Autism Spectrum Disorder (ASD), aiming to provide innovative and effective therapies to meet unmet medical needs.
YTD Price Performance: -21.67%
Average Trading Volume: 691,344
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$48.98M
For detailed information about NTI stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- Intel Stock (NASDAQ:INTC) Slips Despite Growing Interest in AI
- “…Tied to the Effort From the Administration” Boeing Stock (NYSE:BA) Blasts Up as Boeing Counts on New Top Sales Rep in China: President Trump
- “We Do Not Have Conflicting Interests….” Microsoft Stock (NASDAQ:MSFT) Gains on New Plan to be the Agentic AI Internet’s Backbone